Banco de Sabadell S.A Sells 635 Shares of Novo Nordisk A/S (NYSE:NVO)

Banco de Sabadell S.A lessened its position in Novo Nordisk A/S (NYSE:NVO) by 3.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 17,627 shares of the company’s stock after selling 635 shares during the quarter. Banco de Sabadell S.A’s holdings in Novo Nordisk A/S were worth $1,520,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Daiwa Securities Group Inc. acquired a new position in Novo Nordisk A/S during the third quarter valued at approximately $28,000. Center for Financial Planning Inc. raised its stake in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Dunhill Financial LLC boosted its holdings in shares of Novo Nordisk A/S by 196.8% in the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock valued at $56,000 after buying an additional 311 shares during the last quarter. Albion Financial Group UT grew its stake in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after buying an additional 278 shares in the last quarter. Finally, Hager Investment Management Services LLC acquired a new position in Novo Nordisk A/S during the fourth quarter worth $46,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $76.88 on Friday. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a 50 day simple moving average of $83.34 and a 200 day simple moving average of $100.98. Novo Nordisk A/S has a 1-year low of $73.80 and a 1-year high of $148.15. The stock has a market cap of $344.98 billion, a P/E ratio of 23.37, a PEG ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a $0.7874 dividend. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s payout ratio is 47.72%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NVO. Stifel Nicolaus cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Friday. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.